Time to optimal glycaemic control and prognostic factors among type 2 diabetes mellitus patients in public teaching hospitals in Addis Ababa, Ethiopia

Tigist W. Leulseged1*, Birhanu T. Ayele2
1 Department of Internal medicine, St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia, 2 Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

* tigdolly@gmail.com

Abstract

Aim
To estimate time to first optimal glycaemic control and identify prognostic factors among type 2 diabetes mellitus (T2DM) patients attending diabetes clinic of public teaching hospitals in Addis Ababa, Ethiopia.

Methods
A retrospective chart review study was conducted at diabetes clinic of Addis Ababa’s public teaching hospitals among a randomly selected sample of 685 charts of patients with T2DM who were on follow up from January 1, 2013 to June 30, 2017. Data was collected using data abstraction tool. Descriptive statistics, Kaplan Meier plots, median survival time, Log-rank test and Cox proportional hazard survival models were used for analysis.

Results
Median time to first optimal glycaemic control among the study population was 9.5 months. Factors that affect time to first optimal glycaemic control were age group (HR = 0.635, 95% CI: 0.486–0.831 for 50–59 years, HR = 0.558, 95% CI: 0.403–0.771 for 60–69 years and HR = 0.495, 95% CI: 0.310–0.790 for >70 years), diabetes neuropathy (HR = 0.502, 95% CI: 0.375–0.672), more than one complication (HR = 0.381, 95% CI: 0.177–0.816), hypertension (HR = 0.611, 95% CI: 0.486–0.769), dyslipidemia (HR = 0.609, 95% CI: 0.450–0.824), cardiovascular disease (HR = 0.670, 95% CI: 0.458–0.979) and hospital patient being treated (HR = 1.273, 95% CI: 1.052–1.541).

Conclusions
Median time to first optimal glycaemic control among T2DM patients is longer than expected which might imply that patients are being exposed to more risk of complication and death.
Introduction

Diabetes is a chronic, progressive disease characterized by elevated levels of blood glucose. There are three types of diabetes: Type 1, Type 2 and gestational diabetes. Type 2 diabetes is the commonest type[1, 2].

Diabetes is one of the largest global health emergencies of the 21st century. Each year more and more people live with this condition and this increase is noted more rapidly in resource limited countries. According to IDF Atlas and WHO, about 45.1% of all adults aged 20–79 years with diabetes in Africa live in four countries including Ethiopia. In Ethiopia, prevalence of diabetes in adults has increased from 2.9% in 2015 to 3.8% in 2016 to 5.2% in 2017[3–5].

People with diabetes can live longer and have a healthy life if their diabetes is detected early and well-managed, with integrated self-management and health professional support. The longer a person lives with undiagnosed, untreated and/or uncontrolled diabetes, the worse their health outcomes are likely to be. Therefore, controlling blood glucose is key in preventing and slowing the progression of complications [1–4].

Studies conducted in different regions of Ethiopia have focused mainly on level of glycaemic control at one point in time. Majority of the studies show poor glycaemic control (60–80% patients in each study have poor glycaemic control) [6–9]. This is also the case in other countries including Uganda, Kenya, India and China [10–13]. Similarly, a systematic review of literatures from 2011–2015 shows that glycaemic control is suboptimal in majority (typically 40%-60%) of people with diabetes in both low- and higher-income countries [14].

In addition, studies conducted among T2DM patients who has been followed over a period of time has shown that old age, being overweight, long-standing diabetes, high HgA1c, LDL-to-HDL cholesterol ratios, hypertension, micro-albuminuria, and previous cardiovascular disease, are important predictors of poor glycaemic control, morbidity and mortality [12, 15–17].

Though knowing the level of glycaemic control of a patient is an important predictor of development of complication and risk of death from diabetes, the other most important predictor which is the time that the patient stayed in that poor glycaemic level before reaching optimal glycaemic control has not been studied yet.

Patients with same level of poor glycaemic control can have different prognosis because of the difference in the time the patients stayed in that poor glycaemic state. The risk of complication and death increases as the patient stays longer in poor glycaemic level.

The objective of this study was to estimate time to first optimal glycaemic control and identify prognostic factors among T2DM patients attending diabetes clinic of public teaching hospitals in Addis Ababa, Ethiopia.

Methods and materials

2.1 Study design and subjects

The study design was hospital-based retrospective chart review and was conducted at two public teaching hospitals in Addis Ababa: St Paul Hospital Millennium Medical College (SPHMMC) and Yekatit 12 Hospital Medical College (Y12HMC). Both hospitals have a diabetes clinic which is under the department of internal medicine. At Y12HMC patients are seen mainly by General Practitioners (GP) and internists. There was no endocrinologist in the hospital during the study period. At SPHMMC patients are seen by internal medicine residents, internists and endocrinologist. The hospitals do not use the national diabetes management intake and follow up guideline consistently. Medical records and information sheets of new T2DM patients’ who were on follow up from 1stJanuary, 2013 to 31thDecember, 2017 was reviewed.
2.2 Source and Study population

The source population was all new T2DM patients who were on follow up at diabetes clinic of the two hospitals from January 1, 2013 to June 30, 2017. During this interval a total of 1,508 new patients were seen at the two hospitals: 923 patients at SPHMMC and 585 patients at Y12HMC.

The study population was all selected new T2DM patients who full fill the inclusion criteria of >18 years and non-pregnant.

2.3 Sample size and sampling procedure

Sample size was determined by using sample size calculation formula for survival analysis by considering the following statistical assumptions: 95% Confidence Interval (CI), power of 90%, survival probability of 0.5, 5% marginal error, and loss of 20%. The final sample size for this study was 783.

The estimated total sample size was proportionally allocated to the two study sites according to the number of eligible participants in each site. Finally, cards of 417 from SPHMMC and 269 from Y12HMC that fulfilled the criteria were randomly selected and reviewed.

2.4 Operational definitions

Optimal glycaemic control. Optimal glycaemic control is defined as the three consecutive month average fasting blood glucose of 80–130 mg/dl with more or less stringent glycemic goals for individual patients based on age/ life expectancy, comorbid conditions, advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations[18]. N.B: FBS is used as a follow up tool in our set up because HgA1c is not consistently available for patient diagnosis and follow up.

Event. achieving first optimal glycaemic control.

Censoring. patients died, lost to follow-up, transferred out and completed the follow-up period without achieving optimal glycaemic control.

Time to event. time between diagnosis up to achieving first optimal glycaemic control or censoring (in month).

- Start date of the study: 1st January, 2013
- End date of the study: 31st December, 2017

2.5 Data collection

Pre-tested data abstraction tool (questionnaire) that consists of questions to assess the relevant variables was used to collect the necessary data from the patient medical chart by trained data collectors.

2.6 Statistical analysis

The collected data was coded and entered into Epi-Info version 7.2.1.0, cleaned, stored and exported into SPSS version 23 for analysis. Descriptive statistics was presented with frequency tables, Kaplan Meier (KM) plots and median survival times. Kaplan-Meier technique was used to assess survival experience of different groups of patients by using survival curves. Log-rank test was used to assess significant difference among survival distributions of groups for equality.

Univariate analysis was performed to calculate an unadjusted hazard ratio (HR) and to screen out potentially significant independent variables at 25% level of significance.
Association between the significant independent variables and the time to first optimal glycaemic control was assessed using multivariable Cox Proportional Hazard (PH) model. Adjusted hazard ratio (HR), P-value and 95% CI for HR were used to test significance and interpretation of results. Variables with p-value $\leq 0.05$ were considered as statistically associated with the time to first optimal glycaemic control in months.

### 2.7 Ethical considerations

The study was conducted after obtaining ethical clearance from GAMBY Medical and Business College IRB, Addis Ababa Health Bureau, Y12HMC and SPHMMC. Written informed consent was obtained from Endocrinology or Internal medicine department of the hospitals on behalf of the patients. The study had no any risk/negative consequence for study participants. Medical record number was used for the data collection and personal identifiers of the patient were not used in the research report. Access to the collected information was limited to the principal investigator and confidentiality was maintained throughout the project.

### Result

#### 3.1 Censoring status

Among the 685 patients, 483 (70.5%) of the patients achieved optimal glycaemic control while 202 (29.5%) were censored. The median time to achieving optimal glycaemic control was 9.5 months.

#### 3.2 Socio-demographic and institution related variables and censoring status

Majority of the patients (27.7%) were in the age range of 50–59 years, 54.6% of the patients were females and majority of the patients were from Addis Ababa (73.7%). More than half (60.9%) of the patients were from SPHMMC and the rest (39.1%) were from Y12HMC.

Higher proportion of patients in the age group 30–39 achieved optimal glycaemic control, followed by 40–49, 50–59, 60–69 and $\geq 70$ years age groups.

The proportion of patients who achieved optimal glycaemic control among females (73.5%) is higher than males (66.9%). Almost seventy percent (69.9%) of patients from Addis Ababa has achieved optimal glycaemic control. The proportion of patients who achieved optimal glycaemic control at SPHMMC (74.1%) is higher than Y12HMC (64.9%). (Table 1)

#### 3.3 Diabetes related variables (diabetes related complications, diabetes hospitalization and medication) and censoring status

Regarding history of diabetes related complication in general, 32.0% of the patients had history of one or more complications. Majority of the patients had neuropathy (16.9%) followed by acute complication (12.7%), nephropathy (5.1%) and other complication (3.8%). Eighty seven (12.6%) patients had diabetes related hospitalization which was mainly due to acute complication. Oral anti-diabetic drug was given to the majority of patients at the initiation of treatment (83.5%) compared to insulin (16.5%).

The proportion of patients who achieved optimal glycaemic control is higher among those with no history of diabetes related complication (75.8%) compared to those with one or more complication (59.4%).

The proportion of patients who achieved the event is lower among those with more than one diabetes related complication (22.0%) compared to those with only one complication or no complication (73.6%).
The proportion of patients who achieved optimal glycaemic control is comparable among those who were on oral anti-diabetic drug and insulin at the time of initiation of treatment (70.3% Vs 71.7%). (Table 2)

### 3.4 Co-morbid illness and censoring status

More than half (58.8%) of the patients had history of co-morbid illness and 41.2% did not have. Majority of the patients had hypertension (48.6%) followed by dyslipidemia (22.6%), cardiovascular disease (13.9%) and other co-morbid illness (11.1%). More than one fourth of patients (27.6%) had more than one co morbid illness.

The proportion of patients who achieved optimal glycaemic control is higher among those with no history of co-morbid illness (80.9%) than those with one or more co-morbid illness (63.3%). (Table 3)

### Table 1. Socio–demographic and institution related variables and censoring status among T2DM patients, Addis Ababa, 2018 (n = 685).

| Variable                  | Category | Censoring status | Total (%) |
|---------------------------|----------|------------------|-----------|
|                           |          | No censored (%)  | No of event (%) |       |
| Age group in years        | 30–39    | 24 (15.6%)       | 130 (84.4%)    | 154 (22.5%) |
|                           | 40–49    | 36 (22.1%)       | 127 (77.9%)    | 163 (23.8%) |
|                           | 50–59    | 62 (32.6%)       | 128 (67.4%)    | 190 (27.7%) |
|                           | 60–69    | 50 (41.0%)       | 72 (59.0%)     | 122 (17.8%) |
|                           | > = 70   | 30 (53.6%)       | 26 (46.4%)     | 56 (8.2%)   |
| Sex                       | Female   | 99 (26.5%)       | 275 (73.5%)    | 374 (54.6%) |
|                           | Male     | 103 (33.1%)      | 208 (66.9%)    | 311 (45.4%) |
| Region                    | Addis Ababa | 152 (30.1%)    | 353 (69.9%)    | 505 (73.7%) |
|                           | Outside Addis Ababa | 50 (27.8%)       | 130 (72.2%)    | 180 (26.3%) |
| Hospital                  | Yekatit 12 | 94 (35.1%)       | 174 (64.9%)    | 268 (39.1%) |
|                           | St Paul  | 108 (25.9%)      | 309 (74.1%)    | 417 (60.9%) |

https://doi.org/10.1371/journal.pone.0220309.t001

The proportion of patients who achieved optimal glycaemic control is comparable among those who were on oral anti-diabetic drug and insulin at the time of initiation of treatment (70.3% Vs 71.7%). (Table 2)

### Table 2. Diabetes related variables and censoring status among T2DM patients, Addis Ababa, 2018 (n = 685).

| Variable                        | Category | Censoring status | Total (%) |
|---------------------------------|----------|------------------|-----------|
|                                 |          | No censored (%)  | No of event (%) |       |
| History of diabetes related complication | No     | 113 (24.2%)      | 353 (75.8%)    | 466 (68.0%) |
|                                 | Yes      | 89 (40.6%)       | 130 (59.4%)    | 219 (32.0%) |
| Acute complication              | No       | 173 (28.9%)      | 425 (71.1%)    | 598 (87.3%) |
|                                 | Yes      | 29 (33.3%)       | 58 (66.7%)     | 87 (12.7%) |
| Diabetes nephropathy            | No       | 176 (27.1%)      | 474 (72.9%)    | 650 (94.9%) |
|                                 | Yes      | 26 (74.3%)       | 9 (25.7%)      | 35 (5.1%) |
| Diabetes neuropathy             | No       | 145 (25.5%)      | 424 (74.5%)    | 569 (83.1%) |
|                                 | Yes      | 57 (49.1%)       | 59 (50.9%)     | 116 (16.9%) |
| Other complication*             | No       | 189 (28.7%)      | 470 (71.3%)    | 659 (96.2%) |
|                                 | Yes      | 13 (50.0%)       | 13 (50.0%)     | 26 (3.8%) |
| More than one complication      | No       | 170 (26.4%)      | 474 (73.6%)    | 644 (94.0%) |
|                                 | Yes      | 32 (78.0%)       | 9 (22.0%)      | 41 (6.0%) |
| Diabetes related hospitalization| No       | 170 (28.4%)      | 429 (71.6%)    | 599 (87.4%) |
|                                 | Yes      | 32 (37.2%)       | 54 (62.8%)     | 86 (12.6%) |
| Regimen                         | Oral     | 170 (29.7%)      | 402 (70.3%)    | 572 (83.5%) |
|                                 | Insulin  | 32 (28.3%)       | 81 (71.7%)     | 113 (16.5%) |

*Other complication includes diabetes retinopathy, diabetic foot ulcer and diabetes gastropathy

https://doi.org/10.1371/journal.pone.0220309.t002
3.5 Comparison of survival experience

A log rank test was used to assess difference in the survival distribution among groups. The median survival time showed that females achieved optimal glycaemic control in a relatively shorter time (8.6 months) than males (10.3 months). The log rank test was statistically significant ($X^2 (1) = 5.546$, $P$-value = 0.019). As shown in Fig 1 the KM survival function graph also showed that females have a favorable survival (time to achievement of first optimal glycaemic control) experience. The figure shows that, the instantaneous chance of achieving optimal glycaemic control increases for both sexes as the duration of treatment increases.

Regarding age, patients in the age group of 30–39 years showed shorter median time to achieving optimal glycaemic control (5.2 months) followed by patients in the age group 40–49 years (6.5 months). Older patients needed much longer time to achieve optimal glycaemic control; 10.8 months for 50–59 years, 14.8 months for 60–69 years and 28.6 months for > 70 years of age. The survival time was significantly different among the five age groups ($X^2 (4) = 129.010$, $P$-value = 0.000).

Having complications seems to extend time to achieve optimal glycaemic control. The average time to achieve optimal glycaemic control was longer among patients with nephropathy (36.5 months) followed by patients with neuropathy (21.7 months) and other complication (18.7 months) and all show statistically significant (all $p$-values <0.05) difference when compared to the average time of patients with no such complications.

The median time to achieving optimal glycaemic control was longer among patients with cardiovascular disease (20.9 months), those with more than one co-morbid illness (18.4 months), dyslipidemia (16.6 months), other co-morbid illness (16.0 months) and hypertension (14.8 months) and all show statistically significant (all $p$-values <0.05) difference when compared to the median time of patients with no such complications.

The median time to achieving optimal glycaemic control among patients who has been hospitalized is longer (10.7 months) than those who has not been hospitalized (9.7 months) and it was statistically significant ($X^2 (1) = 3.947$, $P$-value = 0.047). *(Table 4)*

3.6 Results of multivariable cox proportional hazard model

The fundamental assumption of Cox Proportional Hazard model, proportional hazards assumption, was tested using Log minus Log function on STATA version 14. Parallel lines

---

Table 3. Co-morbid illness and censoring status among T2DM patients, Addis Ababa, 2018 (n = 685).

| Variable                        | Category | Censoring status | Total (%) |
|---------------------------------|----------|-----------------|-----------|
|                                 |          | No censored (%) | No of event (%) |         |
| History of co-morbid illness   | No       | 54 (19.1%)      | 228 (80.9%)  | 282 (41.2%) |
|                                 | Yes      | 148 (36.7%)     | 255 (63.3%)  | 403 (58.8%) |
| Hypertension                    | No       | 75 (21.3%)      | 277 (78.7%)  | 352 (51.4%) |
|                                 | Yes      | 127 (38.1%)     | 206 (61.9%)  | 333 (48.6%) |
| Dyslipidemia                    | No       | 135 (25.5%)     | 395 (74.5%)  | 530 (77.4%) |
|                                 | Yes      | 67 (43.2%)      | 88 (56.8%)   | 155 (22.6%) |
| Cardiovascular disease          | No       | 152 (25.8%)     | 438 (74.2%)  | 590 (86.1%) |
|                                 | Yes      | 50 (52.6%)      | 45 (47.4%)   | 95 (13.9%)  |
| Other co-morbid illness         | No       | 175 (28.7%)     | 434 (71.3%)  | 609 (88.9%) |
|                                 | Yes      | 27 (35.5%)      | 49 (64.5%)   | 76 (11.1%)  |
| More than one co-morbid illness | No       | 114 (23.0%)     | 382 (77.0%)  | 496 (72.4%) |
|                                 | Yes      | 88 (46.6%)      | 101 (53.4%)  | 189 (27.6%) |

Others*: includes renal disease, neurologic disease, chronic respiratory diseases and thyroid metabolism disorders

[https://doi.org/10.1371/journal.pone.0220309.t003](https://doi.org/10.1371/journal.pone.0220309.t003)
between groups indicate proportionality [19]. Fig 2 reveals that the survival curves seem parallel throughout the study time. These plots show reasonable fit to the proportional hazard assumption.

From univariate analysis of the independent variables at 25% level of significance; sex, age group, diabetes neuropathy, other complication, more than one complication, hypertension, dyslipidemia, cardiovascular disease, other co-morbid illness, more than one co-morbid illness, diabetes related hospitalization and hospital patient being treated were significantly associated with time to optimal glycaemic control among T2DM patients.

However; only age group, diabetes neuropathy, more than one complication, hypertension, dyslipidemia, cardiovascular disease and hospital patient being treated were found to be significantly associated with time to optimal glycaemic control in the multivariable Cox proportional hazard model at 5% level of significance.

The presence of interaction among the independent variables was checked but there was no significant interaction.

Accordingly, after adjusting for other covariates, compared to those in the age range of 30–39 years, the rate of achieving optimal glycaemic control among those in the age group 50–59, 60–69 and > = 70 years were lower by 36.5%, 44.2% and 50.5%, respectively.

The rate of achieving optimal glycaemic control among patients with neuropathy was lower by 49.8% compared to patients with no neuropathy (HR = 0.502, 95% CI = 0.375–0.672, p-value = 0.000). This means, the time needed to reach optimal glycaemic control among patients with no neuropathy was significantly shorter compared with patients with neuropathy.

Similarly, the rate of achieving optimal glycaemic control among patients with more than one complication was 62% lower than patients with no or one complication (HR = 0.381, 95% CI = 0.177–0.816, p-value = 0.013).

Regarding presence of co-morbid illness, after adjusting for other covariates, the rate of achieving optimal glycaemic control among patients with hypertension, dyslipidemia and cardiovascular disease were respectively lower by 38.9%, 39.1% and 33.0% compared to patients with no hypertension, dyslipidemia and cardiovascular disease.
The rate of achieving optimal glycaemic control among patients treated at SPHMMC is 1.273 times patients treated at Y12HMC (HR = 1.273, 95% CI = 1.052–1.541, p-value = 0.013). (Table 5)

**Discussion**

In our study, the median time to achieving optimal glycaemic control was 9.5 months. Though no clear cut off point is set about when to reach optimal glycaemic control, the trend is to have frequent visits and strict follow up for a newly diagnosed T2DM patient till the patient achieves optimal glycaemic control. Therefore, with the measurement tool that we are using for the
study, three consecutive months average fasting blood sugar, patients are expected to reach target at the 3rd month or may be a bit longer than that.

Since there is no previous similar study, the results of this study is compared with cross sectional studies on optimal glycaemic control and survival studies with the event of interest being death and diabetes related morbidity and mortality. The identified prognostic factors of this study are found to be analogous with these literatures.

The age of patients is found to be an important factor that determines time to first optimal glycaemic control. The study shows that the time needed to reach first optimal glycaemic control doesn’t show significant difference between 30–39 and 40–49 years of age. This may be due to the fact that relatively younger patients (30–39 and 40–49) have less co-morbid illness that can affect diabetes disease prognosis and there chance of adherence to follow up and treatment is thought to be relatively better. On the other hand, time needed to reach optimal glycaemic control is longer among patients ≥ 70 years followed by the age group 60–69 and 50–59 years compared to patients in 30–39 years age group indicating that for patients older than 50 years, as age increases the rate of achieving optimal glycaemic control decreases. This finding is in line with studies conducted in Charleston, South Carolina and India[12, 17].

The study found that having diabetes related complication particularly neuropathy and having more than one diabetes related acute or chronic complication is an important prognostic factor. Patients with neuropathy and more than one complication tend to achieve optimal glycaemic control at a rate of 49.8% and 62% lower that of patients with no neuropathy and patients with no or one complication. This is in accordance with a study conducted at Yekatit 12 hospital and Nantong University hospital [10, 15, 20].

In addition, having co-morbid illness is found to be an important prognostic factor that affects time to optimal glycaemic control. The rate of achieving optimal glycaemic control among patients with hypertension, dyslipidemia and cardiovascular disease were lower by 38.9%, 39.1% and 33.0% compared with patients with no such illnesses showing that dyslipidemia has a more negative influence on individual diabetes control followed by hypertension and then cardiovascular disease. This is because having co-morbid illness has effect on diabetes disease progress and could also be due to the effect of taking many drugs which can lead to drug interaction and also decreased drug adherence which interferes with drug effectiveness.
This finding is in line with studies conducted in Charleston, South Carolina, Sweden, Yekatit 12 hospital, Arabian Gulf council countries and Kenya [13, 15–17, 21].

Our study also identified hospital where T2DM patients were treated as one of the factors significantly associated with time to first optimal glycaemic control. The rate of achieving

| Table 5. Results for the final Cox proportional hazard model among T2DM patients, Addis Ababa, 2018 (n = 685). |
|---------------------------------|-----------------|-------------------------------|--------|
| Variables                      | HR (Exp(B))     | 95.0% CI for HR               | Sig.   |
| **Age in years**               |                 |                               |        |
| 30–39 (R)                      |                 |                               |        |
| 40–49                          | 0.808           | (0.627, 1.042)                | 0.101  |
| 50–59                          | 0.635           | (0.486, 0.831)                | 0.001  |
| 60–69                          | 0.558           | (0.403, 0.771)                | 0.000  |
| > = 70                         | 0.495           | (0.310, 0.790)                | 0.003  |
| **Sex**                        |                 |                               |        |
| Female (R)                     | 1               |                               |        |
| Male                           | 0.838           | (0.698, 1.007)                | 0.059  |
| **Diabetes neuropathy**        |                 |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.502           | (0.375, 0.672)                | 0.000* |
| **Other complication**         |                 |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.634           | (0.340, 1.184)                | 0.153  |
| **More than one complication** |                 |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.381           | (0.177, 0.816)                | 0.013* |
| **Hypertension**               |                 |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.611           | (0.486, 0.769)                | 0.000* |
| **Dyslipidemia**               |                 |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.609           | (0.450, 0.824)                | 0.001* |
| **Cardiovascular disease**     |                 |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.670           | (0.458, 0.979)                | 0.039* |
| **Other co-morbid illness**    |                 |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.705           | (0.490, 1.014)                | 0.059  |
| **More than one co-morbid illness** |             |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.891           | (0.589, 1.347)                | 0.583  |
| **Hospital patient being treated** |             |                               |        |
| Yekatit 12 (R)                 | 1               |                               |        |
| St Paul                        | 1.273           | (1.052, 1.541)                | 0.013* |
| **Diabetes related hospitalization** |     |                               |        |
| No (R)                         | 1               |                               |        |
| Yes                            | 0.791           | (0.587, 1.065)                | 0.122  |

* Statistically significant

Note: HR, Hazard ratio; CI, Confidence interval

https://doi.org/10.1371/journal.pone.0220309.t005
optimal glycaemic control among patients at SPHMMC is 27.3% higher than patients at Y12HMC. This difference could be because of difference in underlying population characteristics or unequal sample sizes of the two hospitals, the sample size from SPHMMC was more than 1.5 times the sample size of Y12HMC (268). It could also be due to difference in the level of health professionals who work at the diabetes clinics as having more professional experience and better exposure and training might be an important contributor for better patient management. The other contributing factor could be the non-consistent use of the national diabetes management and follow up guideline. Using the guideline might help the professionals to address all the relevant factors in patient management in a consistent way and might result comparable outcome between the hospitals.

**Conclusion**

Median time to first optimal glycaemic control among T2DM patients attending diabetes clinic of Y12HMC and SPHMMC is longer than expected which might imply that patients are being exposed to more risk of complication and death. This increased risk remains higher for these patients even after they achieved optimal glycaemic control compared to those who achieved optimal glycaemic control in a shorter duration.

**Supporting information**

S1 Dataset. (SAV)

**Acknowledgments**

The authors would like to thank Dr Sisay Sirgu (Endocrinologist at SPHMMC) for his professional advice given during the research work. We wish to thank the hospitals for their cooperation in accessing the HMIS reports and the medical charts of patients. We also would like to thank the supervisors and data collectors for their collaboration and great work during the data collection.

**Author Contributions**

**Conceptualization:** Tigist W. Leulseged, Birhanu T. Ayele.

**Data curation:** Tigist W. Leulseged.

**Formal analysis:** Tigist W. Leulseged.

**Investigation:** Tigist W. Leulseged.

**Methodology:** Tigist W. Leulseged.

**Software:** Tigist W. Leulseged.

**Supervision:** Tigist W. Leulseged, Birhanu T. Ayele.

**Writing – original draft:** Tigist W. Leulseged.

**Writing – review & editing:** Tigist W. Leulseged, Birhanu T. Ayele.

**References**

1. Kumar P, Clark M. Kumar and Clark Clinical Medicine. 6th ed 2014. 248–58 p.

2. Fauci A, Braunwald E, Kasper D. Harrison Principles of Internal Medicine 18th edn ed. New York NY: McGraw Hill Medical; 2015.
3. World Health Organization. Global Report on Diabetes 2016:16–8.
4. International Diabetes Federation. IDF Diabetes Atlas 2017:43–86.
5. International Diabetes Federation. IDF Diabetes Atlas 2015:75–87.
6. Berhane F. Glycemic Control and it’s Associated Factors in Type 2 Diabetic Patients in Suhul Hospital, Northwest Tigray, Ethiopia. Journal of Diabetes & Metabolism 2015; 31(2):131–40.
7. Solomom M, Yemanie B, Alemayehu W, Shitaye A, Nebiyu M. Level of sustained glycemic control and associated factors among patients with diabetes mellitus in Ethiopia: a hospital-based cross-sectional study. Diabetes Metab Syndr Obes. 2015; 8:65–71. https://doi.org/10.2147/DMSO.S75467 PMID: 25657591
8. Tefera K, Tesfahun E, Hailay G. Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia. BMC Res Notes. 2016; 9:78. https://doi.org/10.1186/s13104-016-1896-7 PMID: 28861243
9. Xu F, Zhao L, Su J, Chen T, Wang QG, Chen JF, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetes, metabolic syndrome and obesity. 2014; 6(1)(139).
10. Kibirige D, Akabwai GP, Kampiire L, Kiggundu DS, Lumu W. Frequency and predictors of suboptimal glycemic control in an African diabetic population. Int J Gen Med 2017; 10(33–38). https://doi.org/10.2147/IJG M.S124548 PMID: 28260942
11. Blonde L, Aschner P, Bailey C, Ji L, Leiter L, Matthaei S. Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Global Partnership for Effective Diabetes Management. 2017; 14(3)172–83.
12. Derbachew A, Fikre E, Cheru A. Survival Analysis of Diabetes Mellitus Patients Using Parametric, Non-Parametric and Semi-Parametric Approaches: Addis Ababa, Ethiopia. Ethiopian e-Journal For Research and Innovation Fresight. 2015; 7(1):20–39.
13. CARL J, ULF L, ARNE M, LENNART R. Survival in Patients With Type 2 Diabetes in a Swedish Community. Diabetes Care. 2002; 25(8):1297–302. https://doi.org/10.2337/diacare.25.8.1297 PMID: 12145224
14. Mulugeta G, Leonard E, Cheru Y, Carnae E, Yumin Z. Effect of Trajectories of Glycemic Control on Mortality in Type 2 Diabetes: A Semiparametric Joint Modeling Approach. American Journal of Epidemiology. 2010; 171(10):1090–8. https://doi.org/10.1093/aje/kwq070 PMID: 20427326
15. ADA. Standards of Medical care in Diabtes, Glycaemic targets. 2017 ed2017.
16. Hosmer David and Lemeshow. Applied survival analysis. 2nd edition ed2008.
17. Su J, Zhao L, Zhang X, Cai H, Huang H, Xu F, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovascular diabetology 2018; 17(1)(47). https://doi.org/10.1186/s12933-018-0693-0 PMID: 29598819
18. Mohammed J, Afsana A, Sultana M, Mohammed A, Turk A, Hassan A, et al. Patient related Determinants of Glycemic control in people with Type 2 Diabetes in Gulf Cooperation Council Countries: A systematic review. Journal of Diabetes Research. 2016; 2108:14.